These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 38908003)
21. Crystal structure of a C-terminal deletion mutant of human protein kinase CK2 catalytic subunit. Ermakova I; Boldyreff B; Issinger OG; Niefind K J Mol Biol; 2003 Jul; 330(5):925-34. PubMed ID: 12860116 [TBL] [Abstract][Full Text] [Related]
22. Characterizing the convergence of protein kinase CK2 and caspase-3 reveals isoform-specific phosphorylation of caspase-3 by CK2α': implications for pathological roles of CK2 in promoting cancer cell survival. Turowec JP; Vilk G; Gabriel M; Litchfield DW Oncotarget; 2013 Apr; 4(4):560-71. PubMed ID: 23599180 [TBL] [Abstract][Full Text] [Related]
23. Synthesis and SAR of Tetracyclic Inhibitors of Protein Kinase CK2 Derived from Furocarbazole W16. Kröger L; Daniliuc CG; Ensan D; Borgert S; Nienberg C; Lauwers M; Steinkrüger M; Jose J; Pietsch M; Wünsch B ChemMedChem; 2020 May; 15(10):871-881. PubMed ID: 32168422 [TBL] [Abstract][Full Text] [Related]
24. Proposed Allosteric Inhibitors Bind to the ATP Site of CK2α. Brear P; Ball D; Stott K; D'Arcy S; Hyvönen M J Med Chem; 2020 Nov; 63(21):12786-12798. PubMed ID: 33119282 [TBL] [Abstract][Full Text] [Related]
25. CK2α and CK2α' subunits differ in their sensitivity to 4,5,6,7-tetrabromo- and 4,5,6,7-tetraiodo-1H-benzimidazole derivatives. Janeczko M; Orzeszko A; Kazimierczuk Z; Szyszka R; Baier A Eur J Med Chem; 2012 Jan; 47(1):345-50. PubMed ID: 22115617 [TBL] [Abstract][Full Text] [Related]
26. Development of a high-throughput screening-compatible assay to identify inhibitors of the CK2α/CK2β interaction. Hochscherf J; Lindenblatt D; Steinkrüger M; Yoo E; Ulucan Ö; Herzig S; Issinger OG; Helms V; Götz C; Neundorf I; Niefind K; Pietsch M Anal Biochem; 2015 Jan; 468():4-14. PubMed ID: 25233003 [TBL] [Abstract][Full Text] [Related]
28. Discovery of holoenzyme-disrupting chemicals as substrate-selective CK2 inhibitors. Kufareva I; Bestgen B; Brear P; Prudent R; Laudet B; Moucadel V; Ettaoussi M; Sautel CF; Krimm I; Engel M; Filhol O; Borgne ML; Lomberget T; Cochet C; Abagyan R Sci Rep; 2019 Nov; 9(1):15893. PubMed ID: 31685885 [TBL] [Abstract][Full Text] [Related]
29. Protein Kinase CK2α', More than a Backup of CK2α. Montenarh M; Götz C Cells; 2023 Dec; 12(24):. PubMed ID: 38132153 [TBL] [Abstract][Full Text] [Related]
31. Structural basis of the constitutive activity of protein kinase CK2. Olsen BB; Guerra B; Niefind K; Issinger OG Methods Enzymol; 2010; 484():515-29. PubMed ID: 21036248 [TBL] [Abstract][Full Text] [Related]
32. Unexpected CK2β-antagonistic functionality of bisubstrate inhibitors targeting protein kinase CK2. Pietsch M; Viht K; Schnitzler A; Ekambaram R; Steinkrüger M; Enkvist E; Nienberg C; Nickelsen A; Lauwers M; Jose J; Uri A; Niefind K Bioorg Chem; 2020 Mar; 96():103608. PubMed ID: 32058103 [TBL] [Abstract][Full Text] [Related]
33. Expression and regulation of protein kinase CK2 during the cell cycle. Bosc DG; Lüscher B; Litchfield DW Mol Cell Biochem; 1999 Jan; 191(1-2):213-22. PubMed ID: 10094411 [TBL] [Abstract][Full Text] [Related]
34. Functional specialization of CK2 isoforms and characterization of isoform-specific binding partners. Litchfield DW; Bosc DG; Canton DA; Saulnier RB; Vilk G; Zhang C Mol Cell Biochem; 2001 Nov; 227(1-2):21-9. PubMed ID: 11827170 [TBL] [Abstract][Full Text] [Related]
35. The alpha catalytic subunit of protein kinase CK2 is required for mouse embryonic development. Lou DY; Dominguez I; Toselli P; Landesman-Bollag E; O'Brien C; Seldin DC Mol Cell Biol; 2008 Jan; 28(1):131-9. PubMed ID: 17954558 [TBL] [Abstract][Full Text] [Related]
36. Identification and characterization of a novel testis-specific gene CKT2, which encodes a substrate for protein kinase CK2. Bai X; Silvius D; Chan ED; Escalier D; Xu SX Nucleic Acids Res; 2009 May; 37(8):2699-711. PubMed ID: 19273531 [TBL] [Abstract][Full Text] [Related]
37. KIF5C: a new binding partner for protein kinase CK2 with a preference for the CK2alpha' subunit. Schäfer B; Götz C; Dudek J; Hessenauer A; Matti U; Montenarh M Cell Mol Life Sci; 2009 Jan; 66(2):339-49. PubMed ID: 19011756 [TBL] [Abstract][Full Text] [Related]
38. Structural and Mechanistic Basis of the Inhibitory Potency of Selected 2-Aminothiazole Compounds on Protein Kinase CK2. Lindenblatt D; Nickelsen A; Applegate VM; Jose J; Niefind K J Med Chem; 2020 Jul; 63(14):7766-7772. PubMed ID: 32589844 [TBL] [Abstract][Full Text] [Related]
39. Insights into the Impact of Linker Flexibility and Fragment Ionization on the Design of CK2 Allosteric Inhibitors: Comparative Molecular Dynamics Simulation Studies. Zhou Y; Zhang N; Qi X; Tang S; Sun G; Zhao L; Zhong R; Peng Y Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29301250 [TBL] [Abstract][Full Text] [Related]
40. Protein kinase CK2alpha' is induced by serum as a delayed early gene and cooperates with Ha-ras in fibroblast transformation. Orlandini M; Semplici F; Ferruzzi R; Meggio F; Pinna LA; Oliviero S J Biol Chem; 1998 Aug; 273(33):21291-7. PubMed ID: 9694889 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]